CERS vs. UTMD, ANIK, OSUR, ATRI, LYRA, LUNG, GUTS, TCMD, ANGO, and SGHT
Should you be buying Cerus stock or one of its competitors? The main competitors of Cerus include Utah Medical Products (UTMD), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), Atrion (ATRI), Lyra Therapeutics (LYRA), Pulmonx (LUNG), Fractyl Health (GUTS), Tactile Systems Technology (TCMD), AngioDynamics (ANGO), and Sight Sciences (SGHT). These companies are all part of the "surgical & medical instruments" industry.
Utah Medical Products (NASDAQ:UTMD) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 6.5% of Utah Medical Products shares are owned by insiders. Comparatively, 7.1% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cerus received 415 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 72.23% of users gave Cerus an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.
In the previous week, Utah Medical Products had 6 more articles in the media than Cerus. MarketBeat recorded 8 mentions for Utah Medical Products and 2 mentions for Cerus. Cerus' average media sentiment score of 0.30 beat Utah Medical Products' score of 0.00 indicating that Utah Medical Products is being referred to more favorably in the media.
Utah Medical Products has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.
Cerus has a consensus price target of $3.50, indicating a potential upside of 104.68%. Given Utah Medical Products' higher possible upside, analysts plainly believe Cerus is more favorable than Utah Medical Products.
Utah Medical Products has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.
Utah Medical Products has a net margin of 33.40% compared to Utah Medical Products' net margin of -23.98%. Cerus' return on equity of 13.15% beat Utah Medical Products' return on equity.
Summary
Utah Medical Products beats Cerus on 9 of the 17 factors compared between the two stocks.
Get Cerus News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
